What is already known about this subject• Prior to the worldwide withdrawal of rofecoxib in
2004, due to cardiovascular toxicity with its use, selective COX‐2 inhibitors had been shown …

Aims A postmarketing Prescription‐Event Monitoring study was undertaken to monitor the
safety of rofecoxib, a cyclo‐oxygenase (COX)‐2 selective inhibitor prescribed in primary …

Background Concerns have been raised regarding the cardiovascular safety of the COX‐2
inhibitors. In September 2004, rofecoxib was withdrawn from the market as a result of …

What is already known about this subject• Public concern regarding the cardiovascular
safety of the COX‐2 inhibitors began with the withdrawal of rofecoxib from the market in …

R ofecoxib and a second cyclooxygenase-2 (COX-2) inhibitor, celecoxib, were approved by
the Therapeutic Goods Administration in 1999 after large phase III randomised trials showed …

Purpose To determine the prevalence of chronic use of rofecoxib 50 mg. Rofecoxib is
unusual among nonsteroidal anti‐inflammatory drugs (NSAIDs) in that the licensed dose for …

Rofecoxib (Vioxx), the first COX-2 selective non-steroidal anti-inflammatory drug (NSAID),
was recently withdrawn by Merck Sharp & Dohme. Indeed, both observational studies and …

In 1982 John Robert Vane shared the Nobel Prize with Sune Bergström and Bengt Ingemar
Samuelsson for 'discoveries concerning prostaglandins and related biologically active …

Rofecoxib (Vioxx) was withdrawn from the market because of increased death from
cardiovascular (CV) events. Other selective cyclooxygenase-2 (COX-2) inhibitors and …

An Erratum has been published for this article in Pharmacoepidemiology and Drug Safety
14 (9), 2005, 669. Background The cyclooxygenase‐2 (COX‐2) inhibitor rofecoxib was …